c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines
- PMID: 27104757
- DOI: 10.1667/RR14237.1
c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines
Abstract
We have previously reported that the MEK/ERK pathway sustains in vitro and in vivo transformed phenotype and radioresistance of embryonal rhabdomyosarcoma (ERMS) cell lines. Furthermore, we found that aberrant MEK/ERK signaling activation promotes c-Myc oncoprotein accumulation. In this study, the role of c-Myc in sustaining the ERMS transformed and radioresistant phenotype is characterized. RD and TE671 cell lines conditionally expressing MadMyc chimera protein, c-Myc-dominant negative and shRNA directed to c-Myc were used. Targeting c-Myc counteracted in vitro ERMS adherence and in suspension, growth motility and the expression of pro-angiogenic factors. c-Myc depletion decreased MMP-9, MMP-2, u-PA gelatinolytic activity, neural cell adhesion molecule sialylation status, HIF-1α, VEGF and increased TSP-1 protein expression levels. Rapid but not sustained targeting c-Myc radiosensitized ERMS cells by radiation-induced apoptosis, DNA damage and impairing the expression of DNA repair proteins RAD51 and DNA-PKcs, thereby silencing affected ERMS radioresistance. c-Myc sustains ERMS transformed phenotype and radioresistance by protecting cancer cells from radiation-induced apoptosis and DNA damage, while promoting radiation-induced DNA repair. This data suggest that c-Myc targeting can be tested as a promising treatment in cancer therapy.
Similar articles
-
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.Mol Cancer. 2006 Aug 9;5:31. doi: 10.1186/1476-4598-5-31. Mol Cancer. 2006. PMID: 16899113 Free PMC article.
-
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.Mol Cancer Ther. 2009 Mar;8(3):543-51. doi: 10.1158/1535-7163.MCT-08-0570. Epub 2009 Mar 3. Mol Cancer Ther. 2009. PMID: 19258428
-
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.Mol Cancer. 2016 Feb 20;15:16. doi: 10.1186/s12943-016-0501-y. Mol Cancer. 2016. PMID: 26897742 Free PMC article.
-
c-Myc: linking transformation and genomic instability.Curr Mol Med. 2008 Sep;8(6):446-58. doi: 10.2174/156652408785747988. Curr Mol Med. 2008. PMID: 18781952 Review.
-
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer.Genes (Basel). 2017 Feb 16;8(2):71. doi: 10.3390/genes8020071. Genes (Basel). 2017. PMID: 28212321 Free PMC article. Review.
Cited by
-
Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivo.J Cancer Res Clin Oncol. 2018 Sep;144(9):1685-1699. doi: 10.1007/s00432-018-2696-3. Epub 2018 Jun 29. J Cancer Res Clin Oncol. 2018. PMID: 29959569 Free PMC article.
-
IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway.Biomed Res Int. 2019 Jul 4;2019:7201562. doi: 10.1155/2019/7201562. eCollection 2019. Biomed Res Int. 2019. PMID: 31355278 Free PMC article.
-
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.Cancer Res. 2018 Feb 1;78(3):742-757. doi: 10.1158/0008-5472.CAN-17-1494. Epub 2017 Nov 27. Cancer Res. 2018. PMID: 29180466 Free PMC article.
-
Radiation Response of Human Leukemia/Lymphoma Cells was Improved by 7-Geranyloxycoumarin.Dose Response. 2022 Sep 21;20(3):15593258221124479. doi: 10.1177/15593258221124479. eCollection 2022 Jul-Sep. Dose Response. 2022. PMID: 36158737 Free PMC article.
-
Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization.J Biomed Sci. 2020 Aug 27;27(1):90. doi: 10.1186/s12929-020-00683-6. J Biomed Sci. 2020. PMID: 32854690 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous